This week in Other Barks & Bites, IPWatchdog’s IP news roundup: the House of Representatives passes drug patent legislation, while antitrust legislation targeting patent-related activities is introduced into the Senate and the Trump administration mandates pricing information for pharmaceutical ads; the Patent Trial and Appeal Board (PTAB) issues a pair of precedential decisions on cases with multiple petitions; the USPTO issues marijuana-related trademark guidelines and a notice on modifying patent term adjustment practices; Gilead strikes a settlement with Teva to bring generic Truvada to the U.S. market in 2020; a new music licensing entity is created in Canada; Fourth Circuit rules that bankruptcy can eliminate damages for trade secret violations; and several amicus file briefs asking the U.S. Supreme Court to eliminate the Federal Circuit’s “blocking patent” doctrine.
Other Barks & Bites for Friday, May 10: Congress and Trump Crack Down on Pharma, Amici File Briefs in Acorda, and USPTO to Modify Patent Term Adjustment Procedures
No Comments
Business
- This Week in D.C.: NASA Deep Space Exploration, Small Business and Innovation, and Transportation Sustainability
- Chief Judge Paul Michel: Patent Reform Progress is Likely, But We Must Stay Focused On the Big Picture
- Take Steps to Deter the Spy in Your Business
- Don’t Ignore the Flashing Caution Lights in the Drug Pricing Debate
- Proving a Negative Claim Limitation: A Tale of Three Nonprecedential Cases
Recent Posts
- This Week in D.C.: NASA Deep Space Exploration, Small Business and Innovation, and Transportation Sustainability
- Chief Judge Paul Michel: Patent Reform Progress is Likely, But We Must Stay Focused On the Big Picture
- Take Steps to Deter the Spy in Your Business
- Russia: Court Removes Candidate from Ballot for Social Network Post
- Don’t Ignore the Flashing Caution Lights in the Drug Pricing Debate